-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Jupiter Neurosciences Prices $1M Initial Public Offering Of 2.75M Common Shares At $4.00/Share

Benzinga·12/03/2024 06:58:18
Listen to the news

The Company expects to receive aggregate gross proceeds of $11 million from the Offering, before deducting underwriting discounts and other related expenses.

The Company intends to use the net proceeds from the Offering to fund the Phase II clinical trial of its product candidate JOTROL™ in patients with Parkinson's Disease, Strategic Service Agreements to accelerate business activities in South-East Asia, research and development activities regarding evaluation of new product opportunities, payment of the outstanding annual license fees due to Aquanova AG, the repayment of debt, working capital and other general corporate purposes.